Minimal and Enhanced: Two Legitimate Ways to Develop an Analytical Method

There is a persistent assumption that a more elaborately developed method is a more trustworthy one. ICH Q14 sets out two development approaches, treats both as legitimate, and locates the benefit of the heavier one somewhere other than correctness.

Quick answer

What are the minimal and enhanced approaches? ICH Q14 describes a minimal set of elements that analytical procedure development should include as a baseline, and an enhanced approach that adds systematic knowledge-building on top. Both produce valid methods. The guideline states that applying elements of the enhanced approach leads to better understanding of the impact of procedure parameters on performance and more flexibility for lifecycle management, such as wider operating ranges and a more appropriate set of established conditions.

Flexibility, not accuracy. A minimally developed method that passes validation produces results as valid as an elaborately developed one. What it lacks is room to move later.

The minimal approach: four elements

The guideline says development should include the following as a minimum:

1. Identifying the attributes of the product which need to be tested.
2. Selecting an appropriate technology and related instruments or suitable apparatus.
3. Conducting studies to evaluate performance characteristics such as specificity, accuracy and precision over the reportable range — including the calibration model and the lower and/or higher range limits — and robustness.
4. Documenting the procedure, including the analytical procedure control strategy.

That is a complete and defensible development programme. Everything in it is covered in detail elsewhere in this library: the characteristics in specificity, accuracy and precision, the range in range and linearity, and the documentation in the control strategy.

The enhanced approach: three additions

In addition to the minimal elements, an enhanced approach may include, as appropriate:

• Risk assessment and evaluation of prior knowledge to identify the procedure parameters that can impact performance;
• Uni- or multi-variate experiments and/or modelling to explore ranges and interactions between identified parameters;
• Defining a control strategy including set-points and/or ranges for relevant parameters — which could include proven acceptable ranges (PARs) and/or method operable design regions (MODRs).

The enhanced approach also documents the anticipated performance criteria in an analytical target profile, described in the analytical target profile.

What the extra work buys

ICH Q14 puts the last row concretely: if justified and validated, a proven acceptable range or method operable design region allows movement within the approved ranges to be managed within the company's own quality system, while changes outside those ranges require regulatory communication.

Translated out of the regulatory setting: the work you do up front to learn where a method's edges are is what lets you adjust it afterwards without re-arguing everything. That is also what makes the bridging studies described in bridging studies smaller.

Prior knowledge counts as evidence

ICH Q14 is explicit that development does not start from zero. Prior knowledge is explicitly or implicitly used for informing decisions, and can be internal knowledge from a company's own development and analytical experience, or external knowledge such as scientific and technical publications or established scientific principles.

It goes further, with a point that matters for anyone running routine measurements: existing platform analytical procedures — the guideline's own example is protein content measurement by UV spectroscopy — can be leveraged to evaluate the attributes of a specific product without conducting additional procedure development.

A platform procedure, in the Q2(R2) glossary, is one suitable to test quality attributes of different products without significant change to its operational conditions, system suitability and reporting structure, used on molecules sufficiently alike with respect to the attributes being measured.

Risk management, formal or otherwise

The guideline encourages quality risk management to reduce the risk of poor performance and of reporting incorrect results, with risk assessment typically performed early in development and updated as more information becomes available. It then removes the main objection to doing it: risk assessment can be formal or informal and can be supported by prior knowledge.

The purposes it lists are practical — identify the parameters that could affect performance, assess their potential impact, prioritise which to investigate experimentally, and inform how much ongoing monitoring is needed. The guideline mentions the Ishikawa (cause-and-effect) diagram as one tool.

For a research laboratory, an informal version is a short list: what could make this measurement wrong, which of those is most likely, and what would catch it. That list, written once, is a risk assessment in the sense the guideline means.

Which approach is right for research work

Usually the minimal one, performed honestly — because the flexibility the enhanced approach buys is mostly valuable to organisations that must justify changes to a regulator.

The elements worth borrowing from the enhanced side are the cheap ones:

• Write the requirement first. One paragraph, before choosing a method.
• List what could go wrong. Informally. Once.
• Test the two or three parameters that list identifies, rather than all of them or none.
• Record the ranges you confirmed, so that next year's small adjustment is a known quantity rather than a new experiment.

Key takeaways

• ICH Q14 describes minimal and enhanced development approaches and treats both as legitimate.
• The minimal approach has four elements: identify attributes, select technology, study performance characteristics and robustness, document the procedure and its control strategy.
• The enhanced approach adds risk assessment, experiments or modelling to explore parameter ranges and interactions, and a control strategy with defined ranges.
• The benefit of the enhanced approach is flexibility for lifecycle management, not greater correctness.
• Movement within a justified and validated range can be managed internally; movement outside it cannot.
• Prior knowledge counts, and an existing platform procedure can be used without additional development.
• Risk assessment may be formal or informal, and exists to reduce the risk of reporting incorrect results.

Frequently asked questions

Is a minimally developed method lower quality?

Not in terms of the results it produces. It must clear the same validation bar. What it has less of is documented understanding of its own edges, which costs flexibility later rather than validity now.

What is a proven acceptable range?

A range for a single parameter, established by univariate examination, within which the procedure has been shown to perform acceptably. A method operable design region is the multivariate equivalent: combined ranges for two or more parameters within which the procedure is shown to be fit for purpose.

Do I need an analytical target profile to use the enhanced approach?

The guideline associates the two — the anticipated performance criteria should be documented in an ATP — but formal documentation of the profile is optional. The substance is having written the criteria down.

Can prior knowledge replace experiments?

Partly, and the guideline says so. It informs which parameters to investigate and can reduce how much investigation is needed. It does not replace demonstrating that the procedure performs for its intended purpose.

What does any of this change for a buyer?

Mainly it reframes what to expect from a supplier's methods. A method can be entirely adequate without being elaborate, and elaborateness is not by itself a quality signal. What matters is whether the procedure was shown to do the job it is being used for.

Sources

• International Council for Harmonisation. ICH Harmonised Guideline Q14: Analytical Procedure Development. Final version adopted 1 November 2023. ICH guideline
• International Council for Harmonisation. ICH Harmonised Guideline Q2(R2): Validation of Analytical Procedures. Final version adopted 1 November 2023. ICH guideline

Guideline text is quoted from the adopted ICH documents.

This article describes analytical methodology only. It contains no usage instructions, no dosing information and no protocols of any kind.

For laboratory and in-vitro research use only. Not for human or veterinary use.